Rituximab's cost for the treatment of primary cold agglutinin disease should not limit its use. - Université de Bretagne Occidentale Access content directly
Journal Articles Haematologica Year : 2006

Rituximab's cost for the treatment of primary cold agglutinin disease should not limit its use.

Domains

Human health and pathology

Ghislaine Calvez  : Connect in order to contact the contributor

https://hal.univ-brest.fr/hal-00689153

Submitted on : Thursday, April 19, 2012-1:40:29 PM

Last modification on : Tuesday, October 3, 2023-10:38:03 AM

No file

Dates and versions

hal-00689153 , version 1 (19-04-2012)

Identifiers

  • HAL Id : hal-00689153 , version 1
  • PUBMED : 16533732

Cite

Aurelien Delluc, Elisabeth Pasquier, Luc de Saint Martin, Dominique Mottier. Rituximab's cost for the treatment of primary cold agglutinin disease should not limit its use.. Haematologica, 2006, 91 (3), pp.ECR05. ⟨hal-00689153⟩

Export

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

UNIV-BREST GETBO IBSAM
24 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More